| Identification | Back Directory | [Name]
PRT 060128 (potassiuM) | [CAS]
936501-01-8 | [Synonyms]
PRT 060128 (potassiuM)
PUTUVTXPBZTQMO-UHFFFAOYSA-N | [Molecular Formula]
C20H14ClFKN5O5S2 | [MOL File]
936501-01-8.mol | [Molecular Weight]
562.035 |
| Hazard Information | Back Directory | [Uses]
Elinogrel (PRT060128) potassium is a reversible, competitive and orally active P2Y12 antagonist. Elinogrel potassium inhibits thrombosis[1][2]. | [in vivo]
Elinogrel (60 mg/kg; p.o.; daily for 3 days) inhibits thrombosis[2].
Elinogrel (1 mg/kg; i.v.) blocks residual thrombotic activity observed in clopidogrel (HY-15283)-treated mice (50 mg/kg p.o., 3 days) in a FeCl3 (HY-Y0266)-induced vascular injury model[2]. | Animal Model: | C57BL/6J mice [2] | | Dosage: | 60 mg/kg | | Administration: | P.o.; daily for 3 days | | Result: | Inhibited thrombosis in mouse. |
| [IC 50]
P2Y12 Receptor | [References]
[1] Ueno M, et al. Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiol. 2010 Jul;6(4):445-53. DOI:10.2217/fca.10.67
[2] Haberstock-Debic H, et al. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist. J Pharmacol Exp Ther. 2011 Oct;339(1):54-61. DOI:10.1124/jpet.111.184143 |
|
|